期刊文献+

The expression of cyclooxygenase-2 (COX-2) and p16 in non-Hodgkin's lymphomas and its clinical significance 被引量:4

The expression of cyclooxygenase-2 (COX-2) and p16 in non-Hodgkin's lymphomas and its clinical significance
下载PDF
导出
摘要 Objective: To investigate the expression of cyclooxygenase-2 (COX-2) and p16 proteins in non-Hodgkin's lymphomas (NHL) and their relationship with the genesis and progress of it. Methods: The expression of COX-2 and p16 protein were studied in the lymph nodes tissue from 60 NHL patients and 10 control patients with non-malignant diseases by flow cytometry. Results: Positive rate of COX-2 protein expression in NHL tissues (63.3%, 38/60) was higher than that in normal lymphaden tissues (0, 0/10). The difference was significant between the two groups (P 〈 0.01). Expression of COX-2 protein was related with the clinical stage of NHL. In stage Ⅰ + Ⅱ patients, it was significantly lower (35.0% ± 54.6%) than that in stage Ⅲ + Ⅳ patients (84.6% ±87.5%) (P 〈 0.01). In different sex, age, tumor malignant degree, IPI grade, extranodal involvement and B symptoms groups, the differences of COX-2 expression were not statistically significant (P 〉 0.05). Positive rate of p16 protein expression (41.7%, 25/60) in NHL' was statistically lower than that in normal lymphomas (100%, 10/10) (P 〈 0.01). Expression of p16 protein was related to malignant degree of NHL. The positive rates of p16 protein in low malignant degree tissues (64.7%, 11/17) was higher than that in high malignant degree tissues (14.3%, 2/14) (P 〈 0.05). Positive rates of p16 protein of NHL tissues in different sex, age, IPI grade, extranodal involvement, clinical stages and B symptoms were not statistically significant (P 〉 0.05). The p16 protein expression in COX-2 positive patients was 47.4% (18/38), and in negative patients it was 31.8% (7/22). There was no statistically difference between them (P 〉 0.05). Correlation analysis revealed there was no correlation between expression of COX-2 and p16 protein. Conclusion: Both COX-2 and p16 protein may all have relationship with the genesis and progress of NHL. The expression of COX-2 protein in NHL may be a poor prognostic indicator. COX-2 and p16 protein probably have different mechanisms in the genesis and progress of NHL. Their relationship is firstly put forward in this article and needed further studying.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第2期104-109,共6页 中德临床肿瘤学杂志(英文版)
关键词 non-Hodgkin's lymphomas p16 protein CYCLOOXYGENASE-2 flow cytometry 淋巴肿瘤 临床 化疗 蛋白质
  • 相关文献

参考文献22

  • 1Shimizu D, Vallbohmer D, Kuramochi H, et al. Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2. Int J Cancer. 2006. 119: 765-770.
  • 2Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol, 2004, 31 (2 Suppl 7): 22-29.
  • 3Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res, 2001, 61: 1451-1456.
  • 4Soslow RA, Dannenberg A J, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 2000, 89: 2637-2645.
  • 5Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol, 2001, 76: 26-30.
  • 6Chen WS, Wei S J, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001,91: 894-899.
  • 7Khuri FR, Wu H, Lee J J, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage Ⅰ non-small cell lung cancer. Clin Cancer Res, 2001, 7: 861-867.
  • 8Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60: 1306-1311.
  • 9Wun T, Mcknight H, Tuscano JM. Increased cyclooxygenase-2 (COX- 2): a potential role in the pathogenesis of lymphoma. Leuk Res, 2004, 28: 179-190.
  • 10Hazar B, Ergin M, Seyrek E, et al. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma, 2004, 45: 1395-1399.

同被引文献25

  • 1宋勇罡,王崇高,张明仪,陈吉祥,陆玉琴.血管内皮生长因子C和D在胃癌组织和血清中的表达和意义[J].中华消化外科杂志,2008,7(5). 被引量:5
  • 2程慧敏,毛福珍,王少青,唐采白,王鹏程,王旭波,郭文顺,王颖.幽门螺杆菌相关性胃炎中的非典型增生[J].内镜,1994,11(2):85-86. 被引量:9
  • 3孙元水,叶再元,赵仲生,施敦,邹寿椿.血管内皮生长因子-C和生存素在胃癌组织中的表达及其临床意义[J].中华胃肠外科杂志,2006,9(3):264-267. 被引量:19
  • 4Morita H, Ishikawa Y, Akishima-Fukasawa Y, et al. Histopathological predictor for regional lymph node metastasis in gastric cancer[J].Virchows Arch,2009,454 ( 2 ): 143.
  • 5Lieto E, Ferraraccio F, Orditura M. Expression of vascular endothelial growth factor (VEGF-D) and epidermal growth factor receptor ( EGFR ) is anindependent prognostic indicator of worse outcome in gastric cancer patients[J]. Ann Surg Oncol, 2008,15 ( 1 ) : 69-79.
  • 6Lazar D, Taban S, Ardeleanu C, et al.Inunnnohistochemieal expression of the cyclooxygenase-2 (cox-2) in gastric cancer.The correlations with the tumor angiogenesis and patients' survival[J]. Rom J Morphol Embryol, 2008,49 ( 3 ) : 371-379.
  • 7Lieto E, Ferraraccio F, Orditura M.Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is a~ independent prognostic indicator of worse outcome in gastric cancer patients[J].Ann Surg Oncol,2008,15 ( 1 ): 69-79.
  • 8Ferrandina G, Lauriola L, Distefano MG, et al. Increased Cycloxygenase-2 expression is assoe iated with them otherapy resistance and poor survival in cervica 1 cancer patients[J]. J Clin 0ncol,2002,20 ( 4 ) : 973-981.
  • 9Sugiyama T, Yoshimoto T, Salo R, et al.Endothelin-I induces cyelooxygenase-2 expression and generation of reactive oxygen species in endothelial cells[JJ.J Cardiovasc Pharmaeol, 2004,44 ( 1 ): $332-335~.
  • 10Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarke[J].Expert Rev Mol Diagn, 2008,8 ( 3 ): 30 I-314.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部